SG11201805536VA - Methods for characterizing compositions comprising peanut antigens - Google Patents
Methods for characterizing compositions comprising peanut antigensInfo
- Publication number
- SG11201805536VA SG11201805536VA SG11201805536VA SG11201805536VA SG11201805536VA SG 11201805536V A SG11201805536V A SG 11201805536VA SG 11201805536V A SG11201805536V A SG 11201805536VA SG 11201805536V A SG11201805536V A SG 11201805536VA SG 11201805536V A SG11201805536V A SG 11201805536VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- sanofi
- methods
- bridgewater
- december
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization M1111101110101011111 HO 11111011101 0111101101110011101111111011 11 International Bureau ... ....Yejd (10) International Publication Number (43) International Publication Date ..... ..... WO 2017/115139 A2 6 July 2017 (06.07.2017) WI P0 I P CT (51) International Patent Classification: AO, G01N 33/68 (2006.01) BZ, DO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, PCT/IB2016/001944 KP, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 28 December 2016 (28.12.2016) NI, RU, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/272,094 29 December 2015 (29.12.2015) US kind 16306642.6 8 December 2016 (08.12.2016) EP GM, TZ, of regional protection available): ARIPO (BW, GH, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: SANOFI [FR/FR]; 54, Rue La Boetie, 75008 TJ, Paris (FR). DK, LV, (72) Inventors: ALVING, Kim; C/o Sanofi, 55 Corporate TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Drive, Bridgewater, NJ 08807 (US). WANG, Bing, SM, Huang; C/o Sanofi, 55 Corporate Drive, Bridgewater, NJ GW, KM, ML, MR, NE, SN, TD, TG). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 08807 (US). DEMONTIGNY, Pierre; C/o Sanofi, 55 Published: Corporate Drive, Bridgewater, NJ 08807 (US). — without international search report and to be republished Designated States (unless otherwise indicated, for every upon receipt of that report (Rule 48.2(g)) (81) _ kind of national protection available): AE, AG, AL, AM, = = = = = = = = = = = = = ei C:7 M 11 kin ,-1 ,-1 IN ,-1 © ei (54) Title: METHODS FOR CHARACTERIZING COMPOSITIONS COMPRISING PEANUT ANTIGENS C :) ,..,.. (57) : Methods for determining an in vitro release profile of peanut allergens in a sample are provided. Methods for determ- ining one or more signatures of peanut allergens in a sample are provided.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562272094P | 2015-12-29 | 2015-12-29 | |
| EP16306642 | 2016-12-08 | ||
| PCT/IB2016/001944 WO2017115139A2 (en) | 2015-12-29 | 2016-12-28 | Methods for characterizing compositions comprising peanut antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805536VA true SG11201805536VA (en) | 2018-07-30 |
Family
ID=57629530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805536VA SG11201805536VA (en) | 2015-12-29 | 2016-12-28 | Methods for characterizing compositions comprising peanut antigens |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10466250B2 (en) |
| EP (2) | EP4242663A3 (en) |
| CN (2) | CN114791499A (en) |
| AU (1) | AU2016380894A1 (en) |
| CA (1) | CA3010074A1 (en) |
| DK (1) | DK3397970T3 (en) |
| ES (1) | ES2952741T3 (en) |
| HU (1) | HUE062670T2 (en) |
| MX (1) | MX2018008198A (en) |
| SG (1) | SG11201805536VA (en) |
| WO (1) | WO2017115139A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4242663A3 (en) * | 2015-12-29 | 2023-11-15 | Sanofi | Methods for characterizing compositions comprising peanut antigens |
| US11408895B1 (en) | 2018-04-09 | 2022-08-09 | Hob Biotech Group Corp., Ltd. | Allergen characterization, potent allergen product formulation, comprehensive allergen reagent, and allergy assay |
| TW202346316A (en) | 2022-04-11 | 2023-12-01 | 丹麥商Ａｌｋ 阿貝羅公司 | Peanut allergen composition |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU765211B2 (en) * | 1995-12-29 | 2003-09-11 | University Of Arkansas, The | Peanut allergens and methods |
| DE602005024119D1 (en) * | 2004-03-05 | 2010-11-25 | Prima Meat Packers Ltd | PROCEDURE FOR ALLERGENAWEWEIS |
| EP2140880B1 (en) * | 2008-07-04 | 2012-11-14 | HAL Allergy Holding B.V. | Modification of allergens |
| US8835361B2 (en) * | 2010-06-01 | 2014-09-16 | The Curators Of The University Of Missouri | High-throughput quantitation of crop seed proteins |
| EP2508537A1 (en) * | 2011-04-04 | 2012-10-10 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quantitative standard for mass spectrometry of proteins |
| US9970942B2 (en) * | 2011-09-02 | 2018-05-15 | Dh Technologies Development Pte. Ltd. | System and method for the detection of allergens |
| WO2013087119A1 (en) * | 2011-12-16 | 2013-06-20 | Hal Allergy Holding B.V. | Pharmaceutical formulations and the use thereof for the treatment of peanut allergy |
| US9492535B2 (en) * | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| CN104569243A (en) * | 2014-05-29 | 2015-04-29 | 天津出入境检验检疫局动植物与食品检测中心 | Peanut mass spectrometric detection signature sequence group and detection kit |
| CN104987363A (en) * | 2015-06-25 | 2015-10-21 | 浙江省疾病预防控制中心 | Characteristic peptide of peanut allergen protein and application thereof |
| EP4242663A3 (en) * | 2015-12-29 | 2023-11-15 | Sanofi | Methods for characterizing compositions comprising peanut antigens |
| CA3031176C (en) * | 2016-07-21 | 2024-02-13 | Nisshin Seifun Group Inc. | Allergen detection method |
| WO2021046819A1 (en) * | 2019-09-12 | 2021-03-18 | Mars, Incorporated | Quantifying peanut proteins in food products |
-
2016
- 2016-12-28 EP EP23167597.6A patent/EP4242663A3/en active Pending
- 2016-12-28 CN CN202210259447.5A patent/CN114791499A/en active Pending
- 2016-12-28 ES ES16836233T patent/ES2952741T3/en active Active
- 2016-12-28 AU AU2016380894A patent/AU2016380894A1/en not_active Abandoned
- 2016-12-28 US US15/392,233 patent/US10466250B2/en active Active
- 2016-12-28 DK DK16836233.3T patent/DK3397970T3/en active
- 2016-12-28 HU HUE16836233A patent/HUE062670T2/en unknown
- 2016-12-28 EP EP16836233.3A patent/EP3397970B1/en active Active
- 2016-12-28 CA CA3010074A patent/CA3010074A1/en active Pending
- 2016-12-28 WO PCT/IB2016/001944 patent/WO2017115139A2/en active Application Filing
- 2016-12-28 MX MX2018008198A patent/MX2018008198A/en unknown
- 2016-12-28 CN CN201680082864.XA patent/CN108780097B/en active Active
- 2016-12-28 SG SG11201805536VA patent/SG11201805536VA/en unknown
-
2019
- 2019-09-24 US US16/580,638 patent/US11199548B2/en active Active
-
2021
- 2021-11-10 US US17/523,050 patent/US20220170942A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUE062670T2 (en) | 2023-11-28 |
| CN114791499A (en) | 2022-07-26 |
| EP3397970B1 (en) | 2023-05-24 |
| US10466250B2 (en) | 2019-11-05 |
| EP4242663A3 (en) | 2023-11-15 |
| AU2016380894A1 (en) | 2018-08-09 |
| US11199548B2 (en) | 2021-12-14 |
| ES2952741T3 (en) | 2023-11-03 |
| US20220170942A1 (en) | 2022-06-02 |
| MX2018008198A (en) | 2018-11-12 |
| CN108780097B (en) | 2022-04-05 |
| US20170219600A1 (en) | 2017-08-03 |
| CN108780097A (en) | 2018-11-09 |
| WO2017115139A3 (en) | 2017-08-17 |
| US20200116732A1 (en) | 2020-04-16 |
| EP3397970A2 (en) | 2018-11-07 |
| CA3010074A1 (en) | 2017-07-06 |
| DK3397970T3 (en) | 2023-08-21 |
| WO2017115139A2 (en) | 2017-07-06 |
| EP4242663A2 (en) | 2023-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201805120YA (en) | Zika virus vaccine | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201809024UA (en) | Cancer immunotherapy by immune activation or immune modulation via globo series antigens | |
| SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201804916PA (en) | Three-dimensional polymer networks with channels situated therein | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201804712PA (en) | Biofuel | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201901394XA (en) | Neisseria meningitidis vaccine | |
| SG11201909501TA (en) | Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201805184TA (en) | Combination therapy | |
| SG11201805263TA (en) | Compositions and methods for detecting and treating esophageal cancer |